Gabriel Ghiaur

Johns Hopkins University — United States

Medicine · Health Sciences

30h-index3.6kcitations198works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(92), Retinoids in leukemia and cellular processes(43), Acute Lymphoblastic Leukemia research(31), Hematopoietic Stem Cell Transplantation(25), Chronic Myeloid Leukemia Treatments(16)

Publications197 total

Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation
Leukemia & lymphoma/Leukemia and lymphoma·2026
Cutaneous Melanoma Drives Metabolic Changes in the Aged Bone Marrow Immune Microenvironment
Aging and Cancer·2026Open Access
Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms
Blood·2025Open Access
DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors
Blood·2025· 1 citedOpen Access
5-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients
Blood·2025Open Access
2003 – MOLECULAR DISSECTION OF AGING CLARIFIES THE IMPACT OF MDS GENETICS AND THERAPY
Experimental Hematology·2025
3005 – DIFFERENTIATION, AGING, AND LEUKEMIA ALTER THE METABOLIC PROFILE OF HUMAN BONE MARROW HEMATOPOIETIC STEM AND PROGENITOR CELLS
Experimental Hematology·2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
2025Open Access
FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML
Cancers·2025· 1 citedOpen Access
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
Leukemia Research·2025Open Access
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
2025· 1 citedOpen Access
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies
Cell Death Discovery·2025· 4 citedOpen Access
Arsenic trioxide for reprogramming the bone marrow microenvironment to eliminate acute myeloid leukemia blasts
HemaSphere·2025Open Access
Humanized mouse models in MDS
Cell Death and Disease·2025· 1 citedOpen Access
Differentiation, ageing and leukaemia alter the metabolic profile of human bone marrow haematopoietic stem and progenitor cells
Nature Cell Biology·2025· 5 citedOpen Access
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Blood Neoplasia·2025· 1 citedOpen Access
Comprehensive characterization of human bone marrow microenvironment shows age-related changes
Haematologica·2025Open Access
Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML
2025Open Access
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy
Haematologica·2025· 1 citedOpen Access
Abstract 1170: Decitabine (DAC) induces a DNA damage response (DDR) and synergizes with replication checkpoint inhibitors in acute myeloid leukemia (AML)
Cancer Research·2025
page 1 of 10Next →

Frequent Co-authors

Richard J. Jones(15), Mark J. Levis(12), Ciprian Tomuleasa(8), Lukasz P. Gondek(7), Amy E. DeZern(6), Salvador Alonso(6), W. Brian Dalton(6), Ravi Varadhan(5), Meng Su(5), Ivana Gojo(5), B. Douglas Smith(5), Patric Teodorescu(5), Diana Gulei(4), José A. Cancelas(4), Daniela Hernandez(4), Theodoros Karantanos(4), Gabrielle T. Prince(4), Adrian Bogdan Țigu(3), Dávid Kegyes(3), Brandy Perkins(3)